ArticleAllergy2026
Non-Invasive Scalp Tape-Strip RNA Sequencing Captures Disease Activity and Treatment-Response Signatures in Alopecia Areata.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell transcriptomics reveals epithelial-stromal crosstalk underlying fibrotic remodeling in frontal fibrosing alopecia.iScience · 2026Article
- Non-Invasive Scalp Tape-Strip RNA Sequencing Captures Disease Activity and Treatment-Response Signatures in Alopecia Areata.Allergy · 2026Article
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTape-strip RNA sequencing enables non-invasive molecular profiling of inflammatory skin diseases. However, its ability to capture immune activity, disease severity, and treatment response in alopecia areata (AA)-a follicle-centered autoimmune disorder-has not been systematically evaluated in relation to follicular immune activity and treatment response.
objectivesTo determine whether scalp tape-strip RNA sequencing captures immune pathways associated with disease severity and treatment response in AA, and to assess its concordance with matched scalp biopsies.
methodsWe analyzed 61 RNA-seq profiles, including 46 scalp tape-strip samples (19 healthy controls, 17 active AA, and 10 post-baricitinib samples-five responders and five non-responders) and 15 lesional scalp biopsies. Nine tape-strip-biopsy pairs were obtained from the same scalp region. Batch-corrected expression data were analyzed using covariate-adjusted linear models and gene set-based enrichment analyses interrogating immune, cytotoxic, and follicular epithelial programs.
resultsTape-strip RNA sequencing robustly recapitulated established AA-associated immune signatures, including activation of interferon/JAK-STAT signaling and cytotoxic T/NK cell pathways, together with suppression of follicular epithelial programs. Increasing disease severity was associated with progressive immune activation and epithelial loss. Baricitinib responders showed partial normalization of inflammatory signatures, whereas non-responders retained persistent immune activation, consistent with molecular non-response. Covariate-adjusted models identified treatment response-specific transcriptional changes. Tape-strip and biopsy transcriptomes demonstrated high concordance.
conclusionsScalp tape-strip RNA sequencing captures clinically relevant immune and treatment-responsive molecular signatures in alopecia areata and represents a promising platform for longitudinal immune monitoring and biomarker-driven stratification of treatment response in follicle-centered autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.